APTAMER GROUP
LIVE

Serial Number

79339793

Owner

Aptamer Group Limited

Attorney

Charles J. Meyer

Filing Date

Jun 29, 2021

Add to watchlist:

No watchlists yet
View on USPTO

APTAMER GROUP Trademark

Serial Number: 79339793 • Registration: 7226871

APTAMER GROUP is a trademark filed by Aptamer Group Limited on June 29, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Aptamer Group Limited (3 trademarks)

Second Floor, Bio Centre,

Entity Type: 99

Trademark Details

Filing Date

June 29, 2021

Registration Date

November 28, 2023

Published for Opposition

September 12, 2023

Goods & Services

Reagents for medical use; chemical reagents for medical use; medical, veterinary, clinical, diagnostic and pharmaceutical reagents, agents, chemicals, materials, substances and preparations, namely, clinical medical reagents, reagents for medical use, veterinary diagnostic reagents, chemical reagents for medical purposes, diagnostic agents, preparations and substances for medical purposes; optimised aptamer molecules for medical and veterinary use, namely, veterinary diagnostic reagents, chemical reagents for medical purposes, diagnostic media for bacteriological cultures; medical and veterinary diagnostic reagents and assays for testing of body fluids; medical and veterinary diagnostic test strips for the analysis of blood, urine, saliva, human tissue and animal tissue; diagnostic biomarker reagents for medical and veterinary purposes; reagents and media for medical and veterinary diagnostic or treatment purposes, namely, diagnostic reagents and contrast media for medical use; nucleic acids in the form of diagnostic reagents for medical, veterinary, diagnostic and pharmaceutical purposes, namely nucleic acids and chemical reagents for medical and veterinary purposes; nucleic acid sequences for medical, veterinary, diagnostic and pharmaceutical purposes; diagnostic testing kits comprised of medical diagnostic reagents, assays, monoclonal antibodies, buffers and reagents for testing of bodily fluids, human tissue and animal tissue for use in disease detection; diagnostic reagents for medical and veterinary use for sale in kit form; diagnostic kits comprising specimen receptors and reagents for medical, veterinary and diagnostic testing in the nature of diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids, human tissue and animal tissue for use in disease detection; medical and veterinary diagnostic reagents and assays for testing of fluids

Medical, veterinary and diagnostic services, namely, medical testing for diagnostic or treatment purposes, virus testing for medical diagnostic or treatment purposes, veterinary testing for diagnostic or treatment purposes; medical and veterinary testing services namely, genetic testing for medical, diagnostic and treatment purposes, veterinary testing for diagnostic or treatment purposes; medical and veterinary testing for diagnostic or treatment purposes; medical and veterinary analysis services for diagnostic and treatment purposes, namely, medical analysis for the diagnosis and treatment of persons, medical analysis for the diagnosis and treatment of animals; medical and veterinary testing services relating to diagnosis and treatment; medical and veterinary analysis services, namely, medical analysis for the diagnosis and treatment of persons, medical analysis for the diagnosis and treatment of animals; information and advisory services in respect of the aforementioned services

Research and development services in the field of medical diagnostics and medical testing; product design and development of diagnostic apparatus, instruments, equipment, tools and devices; product research, design and development in the field of diagnostic preparations; product research, design and development of reagents; product research, design and development of aptamer reagents; product research, design and development of aptamer reagents for integration into diagnostic platforms; product research, design and development of reagents for therapeutic applications; product research, design and development of aptamer reagents for therapeutic applications; custom product development of reagents; custom product development of aptamer reagents; medical research, namely, optimsation of aptamer molecules; product research, design and development of nucleic acids for medical, veterinary, diagnostic and pharmaceutical purposes; product research, design and development of nucleic acid sequences for medical, veterinary, diagnostic and pharmaceutical purposes; laboratory testing services namely, testing of pharmaceuticals and medical laboratory testing services; medical and scientific laboratory services for analytical testing; design and development of testing and analysis methods namely, research and development of advanced learning technologies and teaching methods; medical and scientific laboratory services, namely, preparation of biological samples for testing and analysis in research laboratories; medical and veterinary research services; medical and veterinary laboratory services; scientific research and investigations for medical and veterinary purposes; medical and scientific laboratory services, namely, analysis of human and animal tissues and samples for medical and veterinary research; biological research, clinical research, medical research and veterinary research in the field of medical diagnostics and medical testing; provision of information and data relating to medical and veterinary research and development; information and advisory services in respect of the aforementioned services

Medical and veterinary apparatus, instruments, equipment, tools and devices, namely, medical and veterinary apparatus and instruments for use in bodily fluid analysis and testing; medical and veterinary diagnostic apparatus, instruments, equipment, tools and devices, namely, diagnostic apparatus and instruments for use in bodily fluid analysis and testing; medical and veterinary diagnostic apparatus, instruments, equipment, tools and devices for testing for viruses, namely, medical diagnostic apparatus for testing for viruses; apparatus, instruments, equipment, tools and devices for carrying out diagnostic tests for medical and veterinary purposes, namely, medical diagnostic apparatus for testing DNA and RNA samples, medical diagnostic apparatus for testing for viruses, medical diagnostic apparatus for testing of bodily fluids; diagnostic testing kits consisting primarily of probes, buffers and reagents for use in microbial testing; structural parts and fittings for all the aforesaid goods

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Mar 19, 2026 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 26, 2024 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 29, 2024 FICS
FINAL DISPOSITION PROCESSED
Feb 29, 2024 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 28, 2024 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Nov 28, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Nov 28, 2023 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Oct 31, 2023 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 11, 2023 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 11, 2023 OPNR
NOTIFICATION PROCESSED BY IB
Sep 12, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 12, 2023 NPUB
PUBLISHED FOR OPPOSITION
Sep 12, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 23, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Aug 23, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 23, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 9, 2023 CNSA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Aug 5, 2023 RCCK
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 31, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 31, 2023 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jul 31, 2023 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 20, 2023 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 20, 2023 GNSL
SUSPENSION LETTER WRITTEN
Jan 20, 2023 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 16, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 15, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 15, 2022 TROA
REFUSAL PROCESSED BY IB
Jul 6, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 15, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jun 14, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 14, 2022 RFCR
NON-FINAL ACTION WRITTEN
May 13, 2022 CNRT
APPLICATION FILING RECEIPT MAILED
May 10, 2022 MAFR
ASSIGNED TO EXAMINER
May 6, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 6, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 5, 2022 REPR